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Abstract 
 
 
Background: Cancer is the second leading cause of death in economically developed countries. 
The use and availability of oral treatment for cancer has increased dramatically in the past 10 
years. Few studies have described the use of oral chemotherapy in non-traditional ambulatory 
settings by health care professionals across different specialties.  
Objective: The purpose of this study is to describe the usage of oral chemotherapeutic 
medications in ambulatory settings. 
Methods:  Cross sectional study of 2007 NAMCS Survey analysis involving 21,761 subjects 
aged 18 years and above with cancer who participated in the 2007 National Ambulatory Medical 
Survey (NAMCS).  
Main Outcome Measure:  Physician-reported use of oral chemotherapeutic medications 
(includes all major drug classes) as indicated on questionnaire for 2007 NAMCS survey. 
Results: Health care providers in non-traditional settings are less likely to prescribe oral 
chemotherapy than in traditional ambulatory settings (Adjusted odds ratio (AOR)=0.65{95% 
confidence interval: 0.59-0.68}). The study results suggest that oncologists are prescribing oral 
anti-cancer drugs the most as compared to other physician specialties.   
Conclusion: Health care providers in non-traditional settings are less likely to prescribe oral 
chemotherapy than in traditional ambulatory settings. Primary care physicians may have limited 
experience in monitoring and prescribing these potentially toxic medications. Clear guidelines 
are required for the use of oral chemotherapy medications, considering the potential for their use 
in non-traditional ambulatory settings and by non-oncologists. 
 
Keywords: Cancer, Oral Chemotherapeutic medications, cancer surveillance patient setting -
Traditional/Non-Traditional, Physician specialty, oral cytotoxic drug, oral hormonal drug, 
targeted and biological treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
Background/Introduction 
 
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells 
and is a leading cause of death worldwide. According to latest estimates, provided by World 
Health Organization (WHO) 7.4 million people died of cancer in 2004 (approx. 13% of all 
deaths worldwide). If measures are not in place to curtail the growth of cancer diseases, then 10 
million people will be dead by 2030.
1
 In terms of prevalence, lung cancer is the most common 
cancer worldwide, followed by cancer of the breast and colorectal cancer.
1,2  
Cancer is the second 
leading cause of death in economically developed countries and in U.S
1
. In U.S, according to 
most recent report published by American Cancer society about 1,437,180 new cancer cases 
were diagnosed in 2008. These did not include carcinoma in situ, basal and squamous cell skin 
cancers.
1    
 
Oral Chemotherapy refers to the oral use of chemicals or popularly the use of antineoplastic 
drugs to treat cancer and other illnesses such as connective tissues disorders, diseases of immune 
system etc. Chemotherapy is administered traditionally both in the hospital and in the outpatient 
settings including physicians’ offices and outpatient hospital departments using drugs prepared 
by the physicians’ staff or the hospital pharmacy. Patients who receive chemotherapy in 
outpatient settings may be more vulnerable to medication errors due to lack of facilities for 
clinical monitoring, inappropriate dose administration, frequent changes in the doses based on 
the body surface area, and lack of computerized and advanced information technologies.
3-6
 Other 
reasons such as lack of recognition of these errors, existing communication problems, high 
patient load, busy time schedule and fragmentation of care only make the problems worse.
5,7,8
 
  
There are also instances when oncologists prescribe oral chemotherapy on an off label basis.
9-13
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This may be due to lack of sufficient medications for rare diseases and the reimbursement 
policies that constrain the prescription of these medications.
14-16  
 
The use and availability of oral treatment of cancer has increased dramatically in the past 10 
years
13,17,18 
 and may represent up to 25% of all medication used for treatment of cancer in the 
next 5 years.
19  
Yet little or no information is surveyed through the traditional mechanisms of 
cancer surveillance reporting on the use of these medications. The prescribing of oral therapies 
for cancer is expanding to non-oncologic specialties including primary care physicians, who may 
have limited experience in monitoring and prescribing these potentially toxic agents.
3-18,16-19  
  
Surveying the use of these agents by primary care and other non-oncologic specialties is equally 
or perhaps even more important than surveying  information from traditional oncologic practices.  
The new oral treatments require novel approaches to dosing, monitoring of patient adherence to 
prescribed treatment regimens, and monitoring outcomes for which these providers may be 
inadequately trained.
16,19-21  
One of such newer treatments are the targeted therapies which have 
recently become popular and their use is increasing rapidly.
17,22
  These are also known as “small 
molecular drugs”, act at the cellular receptors level, and are administered orally, due to which 
they have significant risks associated with their use. Targeted drugs are likely to represent a 
major proportion (nearly 85%) of anti-neoplastic oral chemotherapy use in the near future.
17,22
 
 
Currently existing cancer surveillance systems do not typically take into consideration the usage 
of oral chemotherapy drugs in traditional hospital outpatient settings, physician offices and in 
non-traditional ambulatory settings.
3,5,8,16,19
  We hypothesize that the prescribing of such 
medications in non-traditional ambulatory settings is non-trivial. Few studies
3-6,8,13,18,23 
compare 
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the safety and efficacy outcomes for the use of oral chemotherapy in non-traditional ambulatory 
settings by non-oncologists. Considering the challenges involved with monitoring and oversight 
of the home administration of these agents outside a controlled clinical environment, such studies 
are warranted. The risk of associated complications coupled with the challenges posed by the 
dosing and monitoring of oral chemotherapy agents highlights the necessity for creating a system 
to capture the data for cancer surveillance on a population basis. The purpose of this study is to 
describe the usage of oral chemotherapeutic medications in non-traditional ambulatory settings. 
The proposed study will attempt to answer the following questions to contribute to the 
knowledge and understanding of the use of chemotherapeutic medications: (1) to estimate the 
prevalence of oral cancer therapy use occurring in non-traditional ambulatory settings (2) to 
analyze the patterns and frequency of use of oral cancer treatment according to insurance status, 
patient settings and by physician specialty. 
 
Methods 
Study Design and Data Variables 
The Institutional Review board of the Virginia Commonwealth University approved this study. 
We used cross-sectional data from the 2007 National Ambulatory Medical Care Survey 
(NAMCS). Briefly, NAMCS is a national probability sample survey of visits to the office-based 
physicians and community health center (CHC).  National Center for Health statistics (NCHS) 
and Center for Disease Control and Prevention (CDC) conducts these surveys annually. The 
surveys are intended to provide useful information on national health statistics and health 
indicators to advance professional education, to serve as a guide for formulation of health policy 
and for quality assurance purpose.
24 
Further, data collected from these surveys also serve as a 
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valuable tool to characterize the changes in utilization and practice of various health care related 
parameters such as changes in diagnosis, tests/procedures and prescribing practices.
24,25 
 
 The basic sampling unit for NAMCS is the physician-patient visit. Traditionally, only visits to 
the offices of nonfederal employed physicians classified by the American Medical Association 
(AMA) or the American Osteopathic Association (AOA) as "office-based, patient care" are 
included in NAMCS. Physicians in the specialties of anesthesiology, pathology, and radiology 
are not included in the survey. Starting in 2006, in addition to the traditional sample, NAMCS 
included a sample of community health centers, using information from the Health Resources 
Services Administration and the Indian Health Service to construct a sampling frame. Visits not 
included in the 2007 NAMCS are following: visits made by telephone, outside the physician's 
office (for example, house calls), visits made in hospital settings, visits made in institutional 
settings by patients for whom the institution has primary responsibility over time (for example, 
nursing homes), and visits to doctors’ offices that are made for administrative purposes only. The 
2007 NAM.CS sample included 3,540 physicians: 3,301 Medical Doctors and 239 Doctors of 
Osteopathy. A total of 1,141 physicians did not meet all of the criteria and were ineligible for the 
study. Of the 2,399 eligible physicians, 1,568 participated in the study. Of these, 1,357 
completed 32,778 Patient Record forms (PRFs). Of the 1,357 physicians who completed PRFs, 
1,266 participated fully or adequately and 91 participated minimally, (i.e. fewer than half of the 
expected number of PRFs were submitted). The 2007 NAMCS used a multistage probability 
design that involved probability samples of primary sampling units (PSUs), physician practices 
within PSUs, and patient visits within practices. The first-stage sample included 112 PSUs. A 
PSU consists of a county, a group of counties, county equivalents (such as parishes and 
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independent cities), towns, townships, minor civil divisions (for some PSUs in New England), or 
a metropolitan statistical area (MSA). The first-stage sample consisted of 112 PSUs that 
comprised a probability subsample of the PSUs used in the 1985-94 National Health Interview 
Survey (NHIS). The NHIS PSU sample was selected from approximately 1,900 geographically 
defined PSUs that covered the 50 States and the District of Columbia. The 1,900 PSUs were 
stratified by socioeconomic and demographic variables and then selected with a probability 
proportional to their size. The second stage consists of a probability sample of practicing 
physicians selected from the master files maintained by the American Medical Association 
(AMA) and American Osteopathic Association (AOA). Within each PSU, all eligible physicians 
are stratified into fifteen specialty groups: general and family practice, osteopathy, internal 
medicine, pediatrics, general surgery, obstetrics and gynecology, orthopedic surgery, 
cardiovascular diseases, dermatology, urology, psychiatry, neurology, ophthalmology, 
otolaryngology, and "all other" specialties. NAMCS sample for 2007 was slightly larger than 
previous years, as the CDC’s National Center for Chronic Disease and Prevention and Health 
Promotion sponsored the inclusion of an additional 200 primary care physicians (general/family 
practice, internal medicine, obstetrics/gynecology, and pediatricians), and the National Cancer 
Institute (NIH) sponsored a supplementary sample of 200 oncologists. The final stage was the 
selection of patient visits within the annual practices of sample physicians. This involved two 
steps. First, the total physician sample was divided into 52 random subsamples of approximately 
equal size, and each subsample was randomly assigned to one of the 52 weeks in the survey year. 
Second, the physician selected a systematic random sample of visits during the assigned week. 
The physician aided by his /her office staff when possible carried out the actual data collection 
for NAMCS. As per instructions, Physicians kept a daily listing of all patient visits during the 
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assigned reporting week using an arrival log, optional worksheet, or similar method. This list 
was the sampling frame to indicate the visits for which data were to be recorded. It was to 
include both scheduled and unscheduled patients. Visits were selected from the list using a 
random start and a predetermined sampling interval based on the physicians estimated visits for 
the week and the number of days the physician was expected to see patients that week. The 
sampling procedures were designed so that about 30 Patient Record forms were completed 
during the assigned reporting week. Some missing data items was imputed by randomly 
assigning a value from a patient record form with similar characteristics. Imputations, in general, 
were based on physician specialty, geographic region, and 3-digit ICD-9-CM codes for primary 
diagnosis. All drugs recodes used Multum drug categories, even those drugs not found in 
Multum’s drug database also used the same. Statistics produced from the 2007 NAMCS were 
derived by a multistage estimation procedure. The procedure produces essentially unbiased 
national estimates and has four components: 1) inflation by reciprocals of the probabilities of 
selection, 2) adjustment for no response, 3) a ratio adjustment to fixed totals, and 4) weight 
smoothing. Physician and patient responses as indicated on a total of 32,778 patient record forms 
(PRF) comprised of self reported data. 
 
 
We included data available from 2007, the most recent data available. We believe that using the 
latest dataset will help us to get the most accurate picture of current practices related to oral 
chemotherapy prescribing in various physician settings, as oral chemotherapeutic agents have 
been available since decades.
47  
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Adults of age 18 years and above with cancer were eligible for our study. This age group was the 
cut-off for our study as there are significant differences in the , spectrum of cancer and its 
treatment for those aged 18 years and above versus the ones below age 18.
23,26-28  
 
 
Determinant 
As a part of our literature review, we found that in certain physician settings, oral chemotherapy 
is administered traditionally and delivery of oral anti-cancer drugs in such settings is deemed 
relatively safe as compared to other clinical settings where there administration poses great risk 
and is not free of dangers related drug side effects and other adverse events.
3-6,8,16,19,23
  Therefore 
based on the findings from our literature review, we defined traditional ambulatory setting as 
physician private solo or group practice. On the other hand, all other settings including 
freestanding clinic/Urgicenter, community health center, mental health center, non-federal 
government clinic, family planning clinic, Health Maintenance organization (HMO) or other 
prepaid practice and faculty practice plan are defined as non-traditional Ambulatory settings.  
 
Outcome Variable 
Based on the literature review
3-6,8,16,19,23
  we categorized Oral chemotherapeutic medications into 
3 categories as 1) oral cytotoxic/anti-neoplastic medications 2) oral hormonal medications and 3) 
orally administered Biological/targeted medications includes oral targeted therapy and small 
molecular agents (Table 1). 
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Analyses 
For our study, we analyzed the quantitative survey data using SAS Version 9.2. Analysis 
included descriptive statistics on demographic, socio-economic and health care characteristics 
for the eligible study population. Analysis also included calculation of estimates of association 
between various patient treatment settings and usage of oral chemotherapeutic agents weighting 
for the complex sampling design. We performed the following statistical tests: frequency 
procedures, crude and adjusted logistic regression analysis. The measure of effect was an odds 
ratio for estimating the likelihood of usage of oral chemotherapy in the non-traditional 
ambulatory setting vs. traditional ambulatory settings.  We included confounders in the logistic 
regression model if their presence resulted in greater than 5% change in the estimates of odds 
ratio. 
 
Results  
After preliminary data analysis, we found a total of N=21,761(weighted N=661,763) patients 
aged 18 years and above with cancer, suitable for oral cancer therapy administration. Table 2 
shows the distribution of exposure groups and various confounders by oral chemotherapy usage 
in traditional and non-traditional ambulatory settings. It appears that oral chemotherapy use is 
more prevalent in traditional ambulatory settings as compared to non-traditional ambulatory 
setting (Figure 1). Various patient characteristics are associated with increasing oral 
chemotherapy use (Table 2). For example, patient’s Age (prescribed more if patients are aged 65 
years and above), Gender (females prescribed more than males), type of health care coverage 
(prescribed more for private and government sponsored insurance than others), Access to 
primary physician (prescribed less if patients have access to at least one primary care physician) 
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and prescribed more if seen earlier in practice. Forty-seven percent of users were over age 65 
whereas only 31% of non-users of oral agents were in this age group.  Eighty percent of users 
were women as compared to 61% of non-users. Racial/ethnic distributions appeared similar 
regardless of oral chemotherapy use. Oncologists are prescribing oral anti-cancer drugs the most 
as compared to other physician specialties (Fig 1). Age was determined to be the only 
confounder in our study and after adjusting for it, we found that health care providers are  less 
likely to prescribe oral chemotherapy in non-traditional ambulatory settings as compared to 
traditional ambulatory settings (Adjusted OR=0.65{95% confidence interval: 0.61-0.69})(Table 
3). It is also evident from (Fig 2) that primary care, surgical care and other physician specialties 
are mainly prescribing oral hormonal, targeted/biological therapy and oral cytotoxic drugs 
respectively. Table 4 provides the crude estimates of potential confounders in our study by use of 
oral chemotherapy. Use of oral agents was less in persons less than 65 years of age as compared 
to elderly persons. Women had 2.5 times the odds of receiving oral agents relative to men (odds 
ratio:  2.53; 95% confidence interval: 2.42-2.65).Patients not seen in the practice before were less 
likely to use oral agents (odds ratio:  0.48; 95% confidence interval: 0.44-0.51). Lack of primary 
care doctor presence was associated with increased odds of an oral agent (odds ratio: 1.38; 95% 
confidence interval:  1.33-1.44). 
 
Discussion 
Magnitude of the Problem  
 
Some of the causes of increased patient visits to physicians’ offices are patient non-compliance 
with self-administered therapy, longer duration of hospital stay and increased physician visits, 
which not only poses hindrance to successful chemotherapy but also results in higher 
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hospitalization rates
 29,30
. Lebovits et al
31
  found that patients coming for treatment to private 
clinics and physician offices were significantly less likely to adhere than the patients coming for 
treatment to university hospitals and other academic settings. Further, in regards to the patient 
taking oral chemotherapy, the study found that patients from lower income and socioeconomic 
status were non-adherent to their treatment in non-oncology settings.
27,31,32
 Another factor for 
non-adherence is the increasing costs
 
incurred to the patient either indirectly such as  non-
medical cost including transportation
33
 or from direct medical cost. For example, recent changes 
in Medicare are responsible for changes in the reimbursement policy for physicians, which in 
some manner can affect the practice patterns leading to visits to non-oncologist doctors for 
chemotherapy.
14-16
 
 
Another important issue that may be related to the prescription of anti-cancer drugs by non-
oncologists is use on an off-label basis, which denotes the use of drugs in populations or disease 
states not listed as indications on the drug’s package insert.9,10 A drug or medical device that is 
used to treat a disease or condition not listed on its label, or used in such a way that is not 
outlined in the label, is referred to as off-label. 
 
The FDA has not officially approved many 
medications that are on the market due to lack of clinical trials and studies on their safety and 
efficacy. Since off-label prescribing happens more often in the ambulatory setting as compared 
to an academic setting, this may be one of the reasons for visits to non-oncologist physician 
practices.
9-12
 Another study
11
 showed that off-label prescribing is widespread in the acute 
hospitalized oncology population, with approximately 22% of all prescriptions for off-label or 
unlicensed medication. Further, off-label prescriptions are mostly for patients with metastatic or 
advanced cancer treated with palliative intent.
5,12
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Walsh et al
23, found that 7% of adult chemotherapy visits and 19% of children’s visits were 
associated with an error in medications used in the clinic or at home. Further, administration of 
chemotherapy medications made up for more than half of the errors detected. Home 
administration errors were more common in children and clinic administration errors more 
common in adults
23
.
  
Gandhi TK et al
8
 reviewed 10,112 medication orders from 1,606 patients 
including adults and children in an ambulatory chemotherapy setting and found that 302 orders 
(3%) were associated with a medication error. The majority of errors occurred in adults with a 
potential for harm, as a result, they were labeled as potential adverse drug events. Another study
6
 
has shown that inpatient medical-surgical error prevalence estimates are 5% i.e. slightly lower as 
compared to the medication errors made in the primary care settings (approximately 8%).  Taylor 
et al observed that a medication error occurred in approximately 10% of cases in which 
chemotherapeutic medications were prescribed for children with ALL in an ambulatory setting. 
Further, more than two-third of the errors were due to faulty prescribing of these medications.
28
 
 
Oral Chemotherapy provides significant advantages from the patients’ perspectives. These 
advantages include patient comfort, flexibility, and no need for repeated and lengthy visits to 
physicians’ offices, convenience associated with home administration, and the improved quality 
of life that is typical for patients treated in palliative setting.
5
 A majority of patients prefers the 
oral form of chemotherapy rather than the intravenous form especially if the efficacy is 
comparable to the intravenous route.
3,4
 However, very little scientific data is available on the true 
safety and efficacy of these drugs for use in general population due to lack of clinical trials. In 
addition, due to insufficient clinical trials, there is no adequate information and guidelines for 
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their appropriate administration to patients. Moreover, very few studies have been conducted in 
the past for directly comparing the safety and efficacy of oral and parental chemotherapeutic 
treatments.
20,21
  
 
Despite the potential benefits, oral chemotherapeutic agents are not free from risks similar to 
those associated with traditional infusion therapy including serious adverse sequel.
5,18,35
 Other 
risks associated with their usage about which patients are often not aware include drug-drug 
interactions, problems related to absorption and other complications resulting from the oral route 
of drug administration.
5,36
 The problem becomes even worse for the oral chemotherapeutic 
agents as there is less standardization in dose calculation and prescribing practices as well as 
availability of fewer other safeguards, standard for the routine infusion therapy. All these 
complications are difficult to monitor when delivered outside the traditional health care settings.
5
 
Financial implications for the patients include rising health care costs due to out of pocket 
payments for drug prescription. In addition, the related out of pocket payments may be 
responsible for creating barriers, which further exacerbates the disparities associated with access 
to the care and outcomes for cancer patients. Disparities related to access to care might affect 
elderly patients with Medicare Part D Insurance, as well as those with lower incomes.
19,37
  On the 
other hand, the overall health care costs to the health care insurance providers/payers for oral 
treatment may be substantially lower than for traditional intravenous infusion therapy since they 
do not require a clinical setting in which these drugs are administered. Therefore, for the health 
care reimbursement system , the cost effectiveness of these medications may be positive.
38-40
 
From the health care provider’s perspective, it appears that due to the differences in methods of 
reimbursement between Europe and the U.S, American Oncologists may be less enthusiastic 
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about oral chemotherapy medicines as Medicare generally does not reimburse the cost of oral 
chemotherapy except when it is in intravenous form.
14-16
  Further, there is often overlap between 
health professionals from different specialties and there is often no clear distinction as to who 
can prescribe and monitor oral chemotherapy due to the lack of guidelines and information on 
the same.
19
 
 
The risk of complications coupled with the challenges in dosing and monitoring the use of oral 
chemotherapeutic agents highlights the necessity for creating a system to capture these data for 
cancer surveillance. Hospitals are working to improve the chemotherapy related prescription 
processes using technologies like e-prescription and electronic medical records but many 
traditional outpatient and physician office practices lack these. Another critical reason to create a 
system to capture data on oral cancer treatment relates to its potential economic impact.  While 
the overall health care costs for administration of oral agents may be lower than for traditional 
office based administration; the costs of these medications are exorbitant
19
 with a 30-day supply 
costing as much as $2000. It is also very important to realize that these drugs are often prescribed 
in combination with other medications, which entails their use over extended periods, probably 
for years, which translates to significant financial costs for both the patient and the health care 
system
19
. Lack of medical insurance and/or out-of-pocket payments may be responsible for 
creating barriers and further exacerbating the disparities linked to access and outcomes for 
cancer patients as per their insurance.
19
 
 
Traditional systems for cancer surveillance, such as hospital based cancer registries; capture 
traditionally administered systemic therapy only 50-75% of time.
41-48
 A potential solution to 
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supplement traditionally administered systemic therapy reporting is to capture data directly in the 
setting where the treatment is provided i.e. physician offices. Systems for monitoring and 
conducting surveillance on the usage of oral chemotherapeutic medications can be developed and 
built upon the existing infrastructure used currently for electronic reporting of controlled 
substances. Systems like these are currently operating in more than 38 states, and are planned for 
an additional 11 states.
40
 Information as gathered from the use of these systems on surveillance 
and monitoring of these drugs will be useful for developing important guidelines and 
recommendations for the usage of oral chemotherapeutic medications in various settings( 
especially non-traditional ones). Health care providers especially in primary care can play a key 
role by facilitating discussion on the important aspects of oral chemotherapy administration with 
the patients in order to guide them and reduce the chances of possible harm resulting from their 
administration. There is also a need for better communication between the patients and their 
providers, to ameliorate the errors resulting from oral chemotherapy administration. 
Incorporating training on these issues for residents and physicians in the form of continuous 
medical education (CME) and educational workshops will also help in preventing medication 
errors and ultimately improve patient care. There is a need for standardizing the dosing for these 
medications distinct from the parentral therapy and establishing certain guidelines to ensure their 
safe administration. Some solutions for improving patient outcomes include double-checking the 
dose before administration, checking patient identity, use of template orders in hospitals and 
outpatient settings to prevent the medication errors until necessary safeguards and guidelines are 
in place.
3,4,7 
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Strengths and Limitations 
Our study has the following strengths: First, the data is analyzed from the National Center for 
Health Statistics (NCHS) database, which includes the National Ambulatory Medical Care 
Survey (NAMCS). NAMCS is a national probability sample survey of visits to office-based 
physicians in the United States and since the sample data are weighted to produce national 
estimates of office visits, the results of this study are generalizable to the U.S. population. 
Second, the study follows a cross-sectional study design, which helps in estimating the current 
weight of the problem and serves as a guide for future public health planning and for designing 
interventions to improve patient care. Some of the limitations of the study are discussed below. 
First; recall bias may be present as responses on questionnaires that were determined at the time 
of the interview. Second, the measures of chemotherapy usage and physician characteristics were 
determined based on self-report. Non-differential misclassification might dilute estimates of 
effect. Nevertheless, this study will serve as a basis for designing more robust research designs.  
 
Conclusion and Future Recommendations: 
More research is needed in the future, considering the fact that an increasing number of oral 
chemotherapeutic medications are being introduced every year in the form of complex regimens, 
which patients have to follow. Clear guidelines are needed for the use of oral chemotherapy 
medications, considering the potential for their use in non-traditional ambulatory settings and by 
non-oncologist specialties. There are currently no robust surveillance mechanisms to monitor the 
use of these medications and capture the information available for them. This certainly calls for 
development of surveillance mechanisms to monitor the use of oral chemotherapeutic 
 19 
 
medications. In the current era of informational technology and use of electronic prescription 
practices, which hold enormous potential for future, there is a strong need for further exploration 
of these modalities to improve the delivery of oral chemotherapy medications and thereby 
improve patient care. There is also a need for effective legislation and policy making to 
formulate specific guidelines for the use of oral chemotherapy. Associations such as the Food 
and Drug Administration (FDA), the American Cancer Society, and other professional medical 
associations can play a pivotal role in collaboration with various government and private 
organizations, including the pharmaceutical companies, in devising suitable legislation and 
policies. 
 
 
We believe that the findings of the study are novel and will help to devise interventions and 
formulate guidelines to reduce the occurrence of inappropriate oral chemotherapeutic prescribing 
practices especially for non-traditional ambulatory settings. 
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Figure 1. Use of Oral Chemotherapy by Patient Setting and physician specialty 
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Figure 2. Type of oral chemotherapy use by physician specialties 
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Table 1 Types of Oral Chemotherapy drug classes 
 
 Oral Cytotoxic/Anti-
Neoplastic 
Oral Hormonal Agents Targeted therapy and 
Biological agents 
Chlorambucil* 
Cyclophosphamide* 
Procarbazine 
Melphalan* 
Busulphan 
Lomustine* 
Temozolomide* 
Azathioprine 
Capecitabine* 
5 -Flurouracil 
Tegafur/Uracil(UFT) 
Thioguanine* 
Hydroxyurea* 
Methotrexate* 
Hydroxycarbamide 
6 Mercaptopurine* 
Thioguanine 
Idarubicin 
Etoposide 
Vinorelbine 
Sirolimus 
Thalidomide* 
Lenalidomide* 
Anastrozole* 
Bicalutamide 
Diethylstilbestrol* 
Exemestane 
Raloxifen* 
Tamoxifen* 
Letrozole 
Megestrol acetate* 
Flutamide 
Bortezomib, 
Dasatinib* 
Imatinib* 
Lapitinib* 
Nilotinib* 
Sorefenib* 
Sunitinib* 
Gefitinib* 
Erlotinib* 
Alemtuzumab 
Bevacizumab 
Gemtuzumab 
Panitumumab 
Rituximab 
Trastuzumab 
*Approved by FDA   
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Table 2 Physician and Patient characteristics by use of oral chemotherapy 
                 Use of Oral Chemotherapy  
   Yes No 
   N=332 N=21429 
   Wt N=11328 Wt N=650435 
      Weighted % Weighted % 
Type of Setting     
 Traditional 91 86 
 Non-Traditional 9 14 
Physician Specialty     
 Oncology  2 1 
 Primary care 51 57 
 Surgical  13 20 
 Others  34 22 
Age of the Patient     
 18-24 years 6 7 
 25-44 years 15 26 
 45-64 years 32 36 
 More than 65 years 47 31 
Race     
 White NH 75 73 
 Black NH  9 10 
 Hispanic  10 12 
 Asians  4 3 
 Others  2 2 
Patient's Gender     
 Male  20 39 
 Female  80 61 
Patient's Health care coverage     
 Private  47 53 
 Medicare/Medicaid 47 37 
 Others  6 10 
Presence of Primary care physician     
 Yes  34 42 
 No  66 58 
Patient seen before in Practice     
 Yes  93 86 
  No   7 14 
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Table 3: Crude and Adjusted Regression Analysis  
    
                  Use of Oral Chemotherapy 
   
    Crude OR (95% CI) 
Adjusted OR* 
(95% CI) 
Full Model 
OR†( 95%CI)  
 Setting     
 Traditional  1.00 1.00 1.00 
  
Non-
Traditional 0.61(0.58-0.65) 0.65(0.61-0.69) 0.63(0.59-0.68) 
* Adjusted for Patients Age 
†
Adjusted for Physician Specialty, Patients Age, Gender, Race, Access to PCP, Seen before in 
Practice and health care coverage  
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Table 4: Crude estimates of potential confounders by Use of Oral chemotherapy 
 
      Crude odds ratios 
      (95%Confidence Intervals) 
Age of the Patient    
 18-24 years  0.56(0.52-0.61) 
 25-44 years  0.37(0.35-0.39) 
 45-64 years  0.59(0.56-0.61) 
 More than 65 years 1.00 
Patient's Gender    
 Female  2.53(2.42-2.65) 
 Male  1.00 
Patient's Race    
 White NH  1.28(1.09-1.50) 
 Black NH  1.12(0.95-1.33) 
 Hispanic  1.11(0.94-1.31) 
 Asian  1.29(1.07-1.55) 
 Others  1.00 
Physician Specialty    
 Oncology  2.16(1.89-2.47) 
 Primary care  0.60(0.58-0.63) 
 Surgical  0.44(0.41-0.46) 
 Others  1.00 
Patient's Health care 
coverage Private  1.38(1.27-1.50) 
 Medicare/Medicaid  2.03(1.87-2.20) 
 Others  1.00 
Presence of Primary care 
physician No  1.38(1.33-1.44) 
 Yes  1.00 
Patient seen before in 
Practice No  0.48(0.44-0.51) 
 Yes  1.00 
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